INS and type 2 diabetes mellitus: While tomosyn inhibitors would seemingly be attractive therapeutics to increase insulin-stimulated glucose uptake by muscle, the potential for elevation of basal glucose uptake, causing hypoglycemia, would require careful consideration as a therapeutic target for prediabetes and T2D.